Replies to post #2198 on Akers Biosciences Inc. (AKER)

[leifsmith]

Looks interesting. Complimentary rather than competitive, except in a very broad sense in which all health restoring drugs are competitive.

[SeanVan]

knuts,
The main difference is MyMD-1 is ready to use now and has been completed pre-clinical and phase-1 and already entered into Phase-2.
Where as Cohbar is still at initial stages and long way to go.
.
Once Phase-2 is complete, which is by the year end, no one can compete with MyMD in those line. My two cent..